Education
About Us
Working with TipRanks
Follow Us
Argent Biopharma (AU:RGT)
ASX:RGT
RGT Stock Chart & Stats
AU$0.08
>-AU$0.01(-2.00%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.32
Previous CloseN/A
Volume362.25K
Average Volume (3M)77.74K
Market Cap
AU$3.96M
Enterprise ValueAU$11.22M
Total Cash (Recent Filing)AU$1.02M
Total Debt (Recent Filing)AU$8.29M
Price to Earnings (P/E)―
Beta-0.84
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding87,942,314
10 Day Avg. Volume131,422
30 Day Avg. Volume77,736
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross Margin (2025)A material gross margin improvement in 2025 indicates the company achieved better pricing, mix, or cost of goods control. That change strengthens unit economics and provides a durable lever for profitability if revenue stabilizes, supporting longer-term margin sustainability and operational flexibility.
Less Negative Free Cash Flow In 2025A move toward less negative free cash flow reduces the company’s cash burn rate and extends runway, lowering immediate financing pressure. If sustained, this trend improves liquidity dynamics and decreases the frequency/size of external capital needs over the medium term.
Notable EPS Growth MetricA reported EPS growth figure suggests a meaningful improvement in per-share earnings dynamics, reflecting operating leverage or reduced losses. Coupled with margin and cash-flow gains, rising EPS points to a structural path toward profitability if the trends persist across upcoming reporting periods.
Bears Say
Negative Shareholders' EquitySustained negative shareholders' equity materially weakens financial flexibility, signaling accumulated losses and eroded capital. This condition typically forces dependence on external financing or equity raises, increasing dilution risk and constraining the company’s ability to invest or absorb shocks over the medium term.
Persistently Negative Free Cash FlowConsistent, material negative free cash flow and zero operating cash flow indicate the business is not self-funding and relies on financing to operate. That persistent cash burn elevates refinancing and liquidity risk and makes long-term planning and investment contingent on securing external capital.
Sharply Contracting Revenue And Large LossesA multi-year revenue contraction combined with large operating losses signals structurally weakening scale and market traction. Shrinking top-line undermines fixed-cost absorption and threatens margin sustainability; reversing this trend is required to realize the improved gross margins and return to durable profitability.
Argent Biopharma News
RGT FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest share price was AU$0.04 and its highest was AU$0.32 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is AU$3.96M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Aug 27, 2026 which is in 162 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -AU$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.038.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 87,942,314 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -AU$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in AU:RGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.17%
12-Months-Change
Fundamentals
Return on Equity
258.94%
Trailing 12-Months
Asset Growth
-29.21%
Trailing 12-Months
Company Description
Argent Biopharma
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Technical Analysis
Genetic Technologies
―
Zelira Therapeutics
―
EVE Health Group Limited
―
Adherium Ltd.
―
Bio-Gene Technology Ltd.
―